TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement
Researchers in Italy tracked data from more than 7,000 patients who underwent AVR between the ages of 65 and 80. TAVR was associated with a significantly higher long-term risk of mortality.
Heart patients benefit when cardiologists follow a standardized TAVR protocol
Using a standardized approach, including the cusp overlap technique, is associated with improved patient outcomes when implanting Medtronic's self-expanding TAVR valves. Researchers tracked data from more than 600 patients treated all over the world, presenting their findings in JSCAI.
How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR
Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.
Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval
After years of trying to catch up with the competition, Boston Scientific is moving on. The company is no longer seeking approval from the FDA or any other regulatory agencies for these devices, and all global sales have been discontinued.
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific TAVR valve linked to positive outcomes after next-day discharge

The self-expanding valve is not yet approved by the FDA, but care teams in other markets are reporting positive outcomes when patients go home the day after treatment.

TAVR and pulmonary hypertension: Key details from a study of 35,000 patients

Patients with pulmonary hypertension are associated with increased short- and long-term risks of death following TAVR. Researchers emphasized the importance of learning as much as possible about this topic going forward.

Market for transcatheter heart valve replacement could top $19B in 10 years

As one may expect, advances in TAVR and TMVR technologies are seen as key drivers of the market’s success.

doctor with overweight patient who may be treated with TAVR or surgery

How persistent AFib impacts TAVR survival

Persistent and paroxysmal atrial fibrillation appear to affect short- and long-term TAVR mortality rates in different ways, according to a new study of nearly 3,000 patients. Some trends fade over time, while others remain in place after many years.

AI can help cardiologists predict death after TAVR—but there is a catch

It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis.

The waiting game: Delaying TAVR increases healthcare costs by $10K per year

Delaying TAVR in eligible patients with severe AS can lead to much higher healthcare costs, according to a new study of real-world Medicare data.

doctor patient discharge after heart surgery

TAVR vs. SAVR for low-risk patients: Cardiologist explores the decision-making process

While multiple studies have confirmed that TAVR and surgery are associated with comparable outcomes, it is important to take an individualized approach to all treatment decisions.

Medtronic TAVR valves at heart of multiple sessions during New York cardiology conference

Medtronic’s TAVR technology received a significant amount of attention during the very first New York Valves conference in New York City. Research focused on patients with small annuli as well as how five-year outcomes compare to surgery.

TAVR

Real-world data favor SAVR over TAVR when younger patients need aortic valve replacement

Heart patients benefit when cardiologists follow a standardized TAVR protocol

How anticoagulants may impact a patient’s risk of gastrointestinal bleeding after TAVR

Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval

Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards